Clinical trials: Pneumococcal Disease, Invasive
Pneumococcal Disease, Invasive
Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants
Phase 2 trial to evaluate safety and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in Healthy Infants
- Trial name
- NCT06790290
- Testing
- Formulation B, Formulation C, Formulation D
- Where
- 3 sites in Philippines
- Volunteers
- 421 people, healthy volunteers welcome
- Sponsor
- Inventprise Inc.
Pneumococcal Infection, Streptococcus Pneumoniae Infection
The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants
Before the introduction of pneumonia vaccines in 2000, between 700,000 - 1 million children died each year as a result of infection with the bacteria Streptococcus pneumoniae and the resulting diseases, namely, meningitis, sepsis…
- Conditions
- Pneumococcal Infection, Streptococcus Pneumoniae Infection, Invasive Pneumococcal Disease, Protection Against
- Trial name
- FPCV (NCT03489018)
- Testing
- PCV10, PCV13
- Where
- Kenya
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Pneumococcal Disease, Invasive
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13
The goal of this clinical trial is to evaluate the immunogenicity and safety of a novel 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13-TT) as compared to Pfizer's 13-valent pneumococcal conjugate vaccine (PCV13)…
- Trial name
- NCT05934890
- Testing
- Walvax PCV13-TT, Pfizer PCV13
- Where
- 2 sites in Indonesia
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection
CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study
This study is assessing if a reduced dosing schedule (1+1) of the 13-valent pneumococcal conjugate vaccine (PCV13) is non-inferior to the currently used schedule used in most of Canada.The vaccine is currently usually given as 3…
- Trial name
- NCT03384589
- Testing
- PCV13
- Where
- Canada
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Invasive Pneumococcal Disease, Recurrent Isolated, 1, Invasive Pneumococcal Disease, Recurrent Isolated, 2
What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?
This is a multicentre prospective audit to determine the incidence of immunodeficiency in children with IPD. Aims and/or research question of the project 1.
- Conditions
- Invasive Pneumococcal Disease, Recurrent Isolated, 1, Invasive Pneumococcal Disease, Recurrent Isolated, 2, Invasive Pneumococcal Disease, Protection Against, Primary Immunodeficiency
- Trial name
- NCT03815357
- Testing
- Referral to Immunology
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Invasive Pneumococcal Disease
Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine
The primary purpose of this study is to evaluate the immune response to 13-valent pneumococcal conjugate vaccine (13vPnCV) in children who as infants received either a complete series of PnCV versus a combination of PnCV and…
- Trial name
- REPLAY (NCT00853749)
- Testing
- 13-valent pneumococcal conjugate vaccine (13vPnC), Blood draw
- Where
- 2 sites in Iceland
- Volunteers
- 89 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Streptococcus Pneumoniae Infection, Streptococcus Pneumoniae, Invasive Disease
Understanding Pneumococcal Carriage and Disease 2017-2020
Streptococcus pneumoniae is a type of bacteria that is carried (lives) in the nose of most individuals and can sometimes go on to cause severe infections such as meningitis and pneumonia.
- Conditions
- Streptococcus Pneumoniae Infection, Streptococcus Pneumoniae, Invasive Disease, Streptococcal Pneumonia
- Trial name
- NCT03102840
- Testing
- Nasopharyngeal swab, blood sampling
- Where
- United Kingdom
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Invasive Pneumococcal Disease
Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease
This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.
- Trial name
- NCT01128439
- Testing
- No intervention
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Acute Upper Respiratory Infection, Acute Lower Respiratory Tract Infection
Impact of Introduction of PHiD-CV for Nunavik Children, Quebec, Canada
The objective of this study is to document the residual burden of acute upper respiratory infections (AURIs), acute lower respiratory infections (ALRIs), otitis media (OMs) and auditory functional and anatomical abnormalities in…
- Conditions
- Acute Upper Respiratory Infection, Acute Lower Respiratory Tract Infection, Otitis Media (OM), Invasive Pneumococcal Disease, Protection Against
- Trial name
- Nunavik2 (NCT01694329)
- Where
- Canada
- Volunteers
- 1,420 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Neisseria Meningitidis (Bacterial Meningitis), Invasive Pneumococcal Disease (IPD)
Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)
The purpose of this study in healthy toddlers who have not previously been immunized against MenC infection and who completed their primary immunization series with PCV-7 (3 vaccinations) during infancy is to demonstrate that the…
- Trial name
- NCT00617760
- Testing
- Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7), 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7), Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)
- Where
- 27 sites in Germany
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Nasopharyngeal Colonization, Invasive Pneumococcal Disease
Impact of PCV on Disease and Colonization Among Native American Communities
The purpose of this study is to determine the impact of pneumococcal conjugate vaccine on carriage of pneumococcus in the nasopharynx and on the incidence of invasive pneumococcal disease in the community.
- Trial name
- NCT01083459
- Where
- 2 sites in United States
- Volunteers
- 6,628 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Invasive Pneumococcal Disease
Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.
The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)
- Trial name
- NCT00227188
- Testing
- Pneumococcal 7-valent conjugate vaccine Prevnar
- Where
- Spain
- Volunteers
- 408 people
- Sponsor
- Pfizer
Pneumonia, Meningitis
Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Lung Fluid of Adults With and Without HIV Infection
Lung immune responses are regulated independently of systemic responses. Injected vaccines may induce optimal responses in blood but not at mucosal surfaces.
- Conditions
- Pneumonia, Meningitis, Invasive Pneumococcal Disease, HIV
- Trial name
- NCT00371878
- Testing
- 7-valent pneumococcal conjugate vaccine (Prevnar)
- Where
- Malawi
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Royal Liverpool University Hospital